<DOC>
	<DOCNO>NCT02521038</DOCNO>
	<brief_summary>Patients acute coronary syndrome ( ACS ) require platelet inhibition treatment . P2Y12 receptor blockage well-known , prove method urgent effective blockade platelet activation , apply current practice protocol . Ticagrelor well-performing P2Y12 receptor block agent use patient . In matter , essential prescribe exact dosage optimize efficacy within safety limit . However current study base Western country , whereas Ticagrelor patient registry East-Asia . Thus reasonable study use Ticagrelor large registry Korean ACS patient . The BK registry Prospective , Open-label , Multi-center , Real world , Registry , prospective registration patient receive medication , Ticagrelor . All subject follow 18 month diagnosis treatment ACS . The purpose study observe register clinical data include Major Adverse Cardiovascular Endpoints total bleeding occurrence Korean ACS patient treat Ticagrelor 18 month follow-up . Also , purpose include determine compliance Ticagrelor post-approval commercial use determine prescription pattern Ticagrelor post-approval commercial use .</brief_summary>
	<brief_title>Use Ticagrelor Korean ACS Patients : The BRILIANT KOREA Registry</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedure . Alternatively , legally authorize patient representative may agree patient 's participation study sign inform consent form . 2 . Patients take ticagrelor acetylsalicylic acid daily Patients take ticagrelor accord label . All treatment modality Acute coronary syndrome ( invasive noninvasive ) allow .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>